Artemisinin Antimalarial Drugs Market Size

Artemisinin Antimalarial Drugs Market Size

Artemisinin Antimalarial Drugs Market was valued at USD 672.2 million in 2023 and is anticipated to grow at a CAGR of 4.2% between 2024 – 2032. The rising incidence of malaria, particularly in tropical and subtropical regions, has increased the demand for effective treatments.

To get key market trends

  Download Free Sample

For instance, as per the CDC, in 2022, an estimated 249 million malaria cases occurred globally, leading to 608,000 malaria deaths in a single year. Such high incidence of malaria cases increases the demand for effective treatments, thereby driving the growth of artemisinin antimalarial drugs market.

Additionally, the emergence of artemisinin-based combination therapies (ACTs) as a gold standard for malaria treatment has significantly contributed to market expansion. Moreover, ongoing research and development efforts aimed at enhancing the efficacy and safety profiles of these drugs coupled with advancements in malaria diagnostics further boost market growth. The global focus on malaria eradication and the support from international organizations, including the World Health Organization, in funding and promoting antimalarial programs also play a crucial role. Furthermore, the growing awareness about the importance of early diagnosis and treatment of malaria supports the demand for artemisinin-based therapies, driving the market forward.

Artemisinin antimalarial drugs are a class of medications derived from the plant Artemisia Annua, commonly known as sweet wormwood. These drugs are primarily used to treat malaria, particularly in cases caused by Plasmodium falciparum. Artemisinin-based treatments are known for their rapid action in reducing parasite load and alleviating symptoms. The most common form of these treatments are artemisinin-based combination therapies (ACTs), which combine artemisinin derivatives with other antimalarial drugs to enhance efficacy and reduce the risk of drug resistance.